Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

Interprofessional Perspectives on Safety Management with Targeted Therapy for B-Cell Malignancies

In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are informational only, should never be considered medical advice, and should never be acted on without review with your health care team.

Interprofessional Perspectives on Safety Management with Targeted Therapy for B-Cell Malignancies

In an educational program from PeerView and CLL Society, an interprofessional team comprised of a hematologist-oncologist (Anthony R. Mato), cardiologist (Dipti Gupta), oncology nurse (Kristen Battiato), and pharmacist (Amber C. King) take a close look at BTK and BCL-2 inhibitors in the B-cell cancer setting and discuss how they collaborate to manage toxicity and safety concerns associated with targeted therapies.

Case scenarios are presented to illustrate how a collaborative approach is not only necessary for managing patients with B-cell cancers, such as CLL and MCL, but can also improve patient outcomes through monitoring and managing adverse events.

This educational program is focused on a healthcare provider audience and eligible for CME credit, but we welcome patient viewers. You will need to complete a short quiz prior to watching the hour-long program.

RECENT NEWS

When appropriate, the CLL Society will be posting updates and background information on the present Coronavirus pandemic focusing on reliable primary sources of information and avoiding most of the news that is not directly from reliable medical experts or government and world health agencies.